nodes	percent_of_prediction	percent_of_DWPC	metapath
Budesonide—CYP3A4—Thiotepa—urinary bladder cancer	0.0424	0.687	CbGbCtD
Budesonide—CYP3A4—Etoposide—urinary bladder cancer	0.0115	0.186	CbGbCtD
Budesonide—NR3C1—urine—urinary bladder cancer	0.011	0.236	CbGeAlD
Budesonide—CYP3A4—urine—urinary bladder cancer	0.00833	0.178	CbGeAlD
Budesonide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00784	0.127	CbGbCtD
Budesonide—NR3C1—Endoderm Differentiation—BPTF—urinary bladder cancer	0.00486	0.0714	CbGpPWpGaD
Budesonide—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00468	0.0688	CbGpPWpGaD
Budesonide—NR3C1—prostate gland—urinary bladder cancer	0.00395	0.0846	CbGeAlD
Budesonide—NR3C1—seminal vesicle—urinary bladder cancer	0.00334	0.0716	CbGeAlD
Budesonide—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.00322	0.0472	CbGpPWpGaD
Budesonide—NR3C1—epithelium—urinary bladder cancer	0.0029	0.0622	CbGeAlD
Budesonide—NR3C1—smooth muscle tissue—urinary bladder cancer	0.0028	0.0599	CbGeAlD
Budesonide—NR3C1—renal system—urinary bladder cancer	0.00269	0.0577	CbGeAlD
Budesonide—NR3C1—urethra—urinary bladder cancer	0.00265	0.0567	CbGeAlD
Budesonide—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00245	0.0359	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.0022	0.0323	CbGpPWpGaD
Budesonide—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00216	0.0318	CbGpPWpGaD
Budesonide—NR3C1—female reproductive system—urinary bladder cancer	0.00216	0.0462	CbGeAlD
Budesonide—CYP3A4—renal system—urinary bladder cancer	0.00204	0.0436	CbGeAlD
Budesonide—NR3C1—vagina—urinary bladder cancer	0.00195	0.0418	CbGeAlD
Budesonide—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.00185	0.0272	CbGpPWpGaD
Budesonide—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00176	0.0258	CbGpPWpGaD
Budesonide—CYP3A4—female reproductive system—urinary bladder cancer	0.00163	0.0349	CbGeAlD
Budesonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.00157	0.0231	CbGpPWpGaD
Budesonide—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.00156	0.0229	CbGpPWpGaD
Budesonide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00154	0.0226	CbGpPWpGaD
Budesonide—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.00134	0.0196	CbGpPWpGaD
Budesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00133	0.0195	CbGpPWpGaD
Budesonide—NR3C1—lymph node—urinary bladder cancer	0.00126	0.027	CbGeAlD
Budesonide—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00123	0.0181	CbGpPWpGaD
Budesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.00123	0.0181	CbGpPWpGaD
Budesonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.000945	0.0139	CbGpPWpGaD
Budesonide—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.000945	0.0139	CbGpPWpGaD
Budesonide—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000945	0.0139	CbGpPWpGaD
Budesonide—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.000895	0.0131	CbGpPWpGaD
Budesonide—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.000863	0.0127	CbGpPWpGaD
Budesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.000847	0.0124	CbGpPWpGaD
Budesonide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000841	0.0124	CbGpPWpGaD
Budesonide—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00083	0.0122	CbGpPWpGaD
Budesonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.000747	0.011	CbGpPWpGaD
Budesonide—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000724	0.0106	CbGpPWpGaD
Budesonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.000709	0.0104	CbGpPWpGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000682	0.01	CbGpPWpGaD
Budesonide—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.000682	0.01	CbGpPWpGaD
Budesonide—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000679	0.00998	CbGpPWpGaD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.000657	0.00965	CbGpPWpGaD
Budesonide—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.000635	0.00933	CbGpPWpGaD
Budesonide—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.000616	0.00905	CbGpPWpGaD
Budesonide—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.000616	0.00905	CbGpPWpGaD
Budesonide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000612	0.000744	CcSEcCtD
Budesonide—Pruritus—Fluorouracil—urinary bladder cancer	0.00061	0.000741	CcSEcCtD
Budesonide—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000609	0.00074	CcSEcCtD
Budesonide—Infestation—Doxorubicin—urinary bladder cancer	0.000609	0.00074	CcSEcCtD
Budesonide—Visual impairment—Methotrexate—urinary bladder cancer	0.000608	0.000739	CcSEcCtD
Budesonide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000602	0.000731	CcSEcCtD
Budesonide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.0006	0.000729	CcSEcCtD
Budesonide—Urticaria—Etoposide—urinary bladder cancer	0.000595	0.000722	CcSEcCtD
Budesonide—Haemoglobin—Epirubicin—urinary bladder cancer	0.000594	0.000721	CcSEcCtD
Budesonide—Rhinitis—Epirubicin—urinary bladder cancer	0.000592	0.000719	CcSEcCtD
Budesonide—Body temperature increased—Etoposide—urinary bladder cancer	0.000592	0.000719	CcSEcCtD
Budesonide—Abdominal pain—Etoposide—urinary bladder cancer	0.000592	0.000719	CcSEcCtD
Budesonide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000592	0.000719	CcSEcCtD
Budesonide—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000592	0.000719	CcSEcCtD
Budesonide—Haemorrhage—Epirubicin—urinary bladder cancer	0.000591	0.000717	CcSEcCtD
Budesonide—Eye disorder—Methotrexate—urinary bladder cancer	0.00059	0.000716	CcSEcCtD
Budesonide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00059	0.000716	CcSEcCtD
Budesonide—Asthenia—Cisplatin—urinary bladder cancer	0.000586	0.000712	CcSEcCtD
Budesonide—Pharyngitis—Epirubicin—urinary bladder cancer	0.000586	0.000712	CcSEcCtD
Budesonide—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000586	0.000712	CcSEcCtD
Budesonide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000583	0.000709	CcSEcCtD
Budesonide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000582	0.000707	CcSEcCtD
Budesonide—Haematuria—Doxorubicin—urinary bladder cancer	0.000581	0.000705	CcSEcCtD
Budesonide—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000581	0.000705	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.00058	0.00852	CbGpPWpGaD
Budesonide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000579	0.000703	CcSEcCtD
Budesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.000577	0.00847	CbGpPWpGaD
Budesonide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000574	0.000698	CcSEcCtD
Budesonide—Angiopathy—Methotrexate—urinary bladder cancer	0.000573	0.000696	CcSEcCtD
Budesonide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000571	0.000694	CcSEcCtD
Budesonide—Immune system disorder—Methotrexate—urinary bladder cancer	0.00057	0.000692	CcSEcCtD
Budesonide—Dizziness—Fluorouracil—urinary bladder cancer	0.00057	0.000692	CcSEcCtD
Budesonide—Visual impairment—Epirubicin—urinary bladder cancer	0.000569	0.000691	CcSEcCtD
Budesonide—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000569	0.000691	CcSEcCtD
Budesonide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000559	0.000679	CcSEcCtD
Budesonide—Alopecia—Methotrexate—urinary bladder cancer	0.000558	0.000677	CcSEcCtD
Budesonide—Vomiting—Gemcitabine—urinary bladder cancer	0.000558	0.000677	CcSEcCtD
Budesonide—Mental disorder—Methotrexate—urinary bladder cancer	0.000553	0.000672	CcSEcCtD
Budesonide—Rash—Gemcitabine—urinary bladder cancer	0.000553	0.000671	CcSEcCtD
Budesonide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000552	0.000671	CcSEcCtD
Budesonide—Eye disorder—Epirubicin—urinary bladder cancer	0.000552	0.000671	CcSEcCtD
Budesonide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000552	0.00067	CcSEcCtD
Budesonide—Malnutrition—Methotrexate—urinary bladder cancer	0.00055	0.000667	CcSEcCtD
Budesonide—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000549	0.000667	CcSEcCtD
Budesonide—Headache—Gemcitabine—urinary bladder cancer	0.000549	0.000667	CcSEcCtD
Budesonide—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000548	0.000666	CcSEcCtD
Budesonide—Flushing—Epirubicin—urinary bladder cancer	0.000548	0.000666	CcSEcCtD
Budesonide—Vomiting—Fluorouracil—urinary bladder cancer	0.000548	0.000666	CcSEcCtD
Budesonide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000548	0.000666	CcSEcCtD
Budesonide—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000547	0.000664	CcSEcCtD
Budesonide—Rash—Fluorouracil—urinary bladder cancer	0.000544	0.00066	CcSEcCtD
Budesonide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000543	0.00066	CcSEcCtD
Budesonide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000543	0.000659	CcSEcCtD
Budesonide—Headache—Fluorouracil—urinary bladder cancer	0.00054	0.000656	CcSEcCtD
Budesonide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00054	0.000656	CcSEcCtD
Budesonide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000539	0.000654	CcSEcCtD
Budesonide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000538	0.000654	CcSEcCtD
Budesonide—Asthenia—Etoposide—urinary bladder cancer	0.000537	0.000652	CcSEcCtD
Budesonide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000537	0.000652	CcSEcCtD
Budesonide—Angiopathy—Epirubicin—urinary bladder cancer	0.000536	0.000651	CcSEcCtD
Budesonide—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000536	0.000651	CcSEcCtD
Budesonide—Immune system disorder—Epirubicin—urinary bladder cancer	0.000534	0.000648	CcSEcCtD
Budesonide—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000532	0.000647	CcSEcCtD
Budesonide—Back pain—Methotrexate—urinary bladder cancer	0.000532	0.000646	CcSEcCtD
Budesonide—Pruritus—Etoposide—urinary bladder cancer	0.00053	0.000643	CcSEcCtD
Budesonide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000527	0.00064	CcSEcCtD
Budesonide—Alopecia—Epirubicin—urinary bladder cancer	0.000522	0.000634	CcSEcCtD
Budesonide—Nausea—Gemcitabine—urinary bladder cancer	0.000521	0.000633	CcSEcCtD
Budesonide—Vomiting—Cisplatin—urinary bladder cancer	0.00052	0.000631	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.000518	0.00761	CbGpPWpGaD
Budesonide—Vision blurred—Methotrexate—urinary bladder cancer	0.000518	0.000629	CcSEcCtD
Budesonide—Mental disorder—Epirubicin—urinary bladder cancer	0.000518	0.000629	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.000516	0.00758	CbGpPWpGaD
Budesonide—Rash—Cisplatin—urinary bladder cancer	0.000515	0.000626	CcSEcCtD
Budesonide—Dermatitis—Cisplatin—urinary bladder cancer	0.000515	0.000625	CcSEcCtD
Budesonide—Malnutrition—Epirubicin—urinary bladder cancer	0.000514	0.000625	CcSEcCtD
Budesonide—Diarrhoea—Etoposide—urinary bladder cancer	0.000512	0.000622	CcSEcCtD
Budesonide—Nausea—Fluorouracil—urinary bladder cancer	0.000512	0.000622	CcSEcCtD
Budesonide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000511	0.00062	CcSEcCtD
Budesonide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00051	0.000619	CcSEcCtD
Budesonide—Anaemia—Methotrexate—urinary bladder cancer	0.000508	0.000617	CcSEcCtD
Budesonide—Flushing—Doxorubicin—urinary bladder cancer	0.000507	0.000616	CcSEcCtD
Budesonide—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000507	0.000616	CcSEcCtD
Budesonide—Flatulence—Epirubicin—urinary bladder cancer	0.000507	0.000615	CcSEcCtD
Budesonide—Tension—Epirubicin—urinary bladder cancer	0.000505	0.000613	CcSEcCtD
Budesonide—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000504	0.0074	CbGpPWpGaD
Budesonide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000504	0.000612	CcSEcCtD
Budesonide—Nervousness—Epirubicin—urinary bladder cancer	0.0005	0.000607	CcSEcCtD
Budesonide—Back pain—Epirubicin—urinary bladder cancer	0.000497	0.000604	CcSEcCtD
Budesonide—Angiopathy—Doxorubicin—urinary bladder cancer	0.000496	0.000602	CcSEcCtD
Budesonide—Malaise—Methotrexate—urinary bladder cancer	0.000496	0.000602	CcSEcCtD
Budesonide—Dizziness—Etoposide—urinary bladder cancer	0.000495	0.000601	CcSEcCtD
Budesonide—Muscle spasms—Epirubicin—urinary bladder cancer	0.000494	0.0006	CcSEcCtD
Budesonide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000494	0.0006	CcSEcCtD
Budesonide—Vertigo—Methotrexate—urinary bladder cancer	0.000494	0.0006	CcSEcCtD
Budesonide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000493	0.000598	CcSEcCtD
Budesonide—Nausea—Cisplatin—urinary bladder cancer	0.000486	0.00059	CcSEcCtD
Budesonide—Vision blurred—Epirubicin—urinary bladder cancer	0.000485	0.000589	CcSEcCtD
Budesonide—Alopecia—Doxorubicin—urinary bladder cancer	0.000483	0.000587	CcSEcCtD
Budesonide—Cough—Methotrexate—urinary bladder cancer	0.00048	0.000582	CcSEcCtD
Budesonide—Mental disorder—Doxorubicin—urinary bladder cancer	0.000479	0.000582	CcSEcCtD
Budesonide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000477	0.00058	CcSEcCtD
Budesonide—Vomiting—Etoposide—urinary bladder cancer	0.000476	0.000578	CcSEcCtD
Budesonide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000476	0.000578	CcSEcCtD
Budesonide—Anaemia—Epirubicin—urinary bladder cancer	0.000475	0.000577	CcSEcCtD
Budesonide—Agitation—Epirubicin—urinary bladder cancer	0.000473	0.000574	CcSEcCtD
Budesonide—Rash—Etoposide—urinary bladder cancer	0.000472	0.000573	CcSEcCtD
Budesonide—Dermatitis—Etoposide—urinary bladder cancer	0.000472	0.000573	CcSEcCtD
Budesonide—Headache—Etoposide—urinary bladder cancer	0.000469	0.00057	CcSEcCtD
Budesonide—Flatulence—Doxorubicin—urinary bladder cancer	0.000469	0.000569	CcSEcCtD
Budesonide—Chest pain—Methotrexate—urinary bladder cancer	0.000468	0.000568	CcSEcCtD
Budesonide—Arthralgia—Methotrexate—urinary bladder cancer	0.000468	0.000568	CcSEcCtD
Budesonide—Myalgia—Methotrexate—urinary bladder cancer	0.000468	0.000568	CcSEcCtD
Budesonide—Tension—Doxorubicin—urinary bladder cancer	0.000467	0.000567	CcSEcCtD
Budesonide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000466	0.000566	CcSEcCtD
Budesonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000465	0.000564	CcSEcCtD
Budesonide—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000464	0.00681	CbGpPWpGaD
Budesonide—Malaise—Epirubicin—urinary bladder cancer	0.000464	0.000563	CcSEcCtD
Budesonide—Discomfort—Methotrexate—urinary bladder cancer	0.000462	0.000561	CcSEcCtD
Budesonide—Nervousness—Doxorubicin—urinary bladder cancer	0.000462	0.000561	CcSEcCtD
Budesonide—Vertigo—Epirubicin—urinary bladder cancer	0.000462	0.000561	CcSEcCtD
Budesonide—Syncope—Epirubicin—urinary bladder cancer	0.000461	0.00056	CcSEcCtD
Budesonide—Back pain—Doxorubicin—urinary bladder cancer	0.00046	0.000559	CcSEcCtD
Budesonide—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000458	0.00672	CbGpPWpGaD
Budesonide—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000458	0.000556	CcSEcCtD
Budesonide—Palpitations—Epirubicin—urinary bladder cancer	0.000455	0.000552	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000452	0.00664	CbGpPWpGaD
Budesonide—Confusional state—Methotrexate—urinary bladder cancer	0.000452	0.000549	CcSEcCtD
Budesonide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000452	0.000549	CcSEcCtD
Budesonide—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.00045	0.00661	CbGpPWpGaD
Budesonide—Cough—Epirubicin—urinary bladder cancer	0.000449	0.000545	CcSEcCtD
Budesonide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000449	0.000545	CcSEcCtD
Budesonide—Vision blurred—Doxorubicin—urinary bladder cancer	0.000448	0.000545	CcSEcCtD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000448	0.00658	CbGpPWpGaD
Budesonide—Infection—Methotrexate—urinary bladder cancer	0.000446	0.000541	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000445	0.00654	CbGpPWpGaD
Budesonide—Nausea—Etoposide—urinary bladder cancer	0.000445	0.00054	CcSEcCtD
Budesonide—Hypertension—Epirubicin—urinary bladder cancer	0.000444	0.000539	CcSEcCtD
Budesonide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000442	0.000536	CcSEcCtD
Budesonide—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.00044	0.00646	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.00044	0.00646	CbGpPWpGaD
Budesonide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00044	0.000534	CcSEcCtD
Budesonide—Anaemia—Doxorubicin—urinary bladder cancer	0.00044	0.000534	CcSEcCtD
Budesonide—Chest pain—Epirubicin—urinary bladder cancer	0.000438	0.000532	CcSEcCtD
Budesonide—Myalgia—Epirubicin—urinary bladder cancer	0.000438	0.000532	CcSEcCtD
Budesonide—Arthralgia—Epirubicin—urinary bladder cancer	0.000438	0.000532	CcSEcCtD
Budesonide—Agitation—Doxorubicin—urinary bladder cancer	0.000437	0.000531	CcSEcCtD
Budesonide—Anxiety—Epirubicin—urinary bladder cancer	0.000436	0.00053	CcSEcCtD
Budesonide—Skin disorder—Methotrexate—urinary bladder cancer	0.000436	0.000529	CcSEcCtD
Budesonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000435	0.000528	CcSEcCtD
Budesonide—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000434	0.00637	CbGpPWpGaD
Budesonide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000434	0.000527	CcSEcCtD
Budesonide—Discomfort—Epirubicin—urinary bladder cancer	0.000433	0.000525	CcSEcCtD
Budesonide—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000432	0.00635	CbGpPWpGaD
Budesonide—Malaise—Doxorubicin—urinary bladder cancer	0.000429	0.000521	CcSEcCtD
Budesonide—Dry mouth—Epirubicin—urinary bladder cancer	0.000428	0.00052	CcSEcCtD
Budesonide—Vertigo—Doxorubicin—urinary bladder cancer	0.000428	0.000519	CcSEcCtD
Budesonide—Anorexia—Methotrexate—urinary bladder cancer	0.000428	0.000519	CcSEcCtD
Budesonide—Syncope—Doxorubicin—urinary bladder cancer	0.000427	0.000518	CcSEcCtD
Budesonide—Confusional state—Epirubicin—urinary bladder cancer	0.000423	0.000514	CcSEcCtD
Budesonide—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000421	0.00618	CbGpPWpGaD
Budesonide—Palpitations—Doxorubicin—urinary bladder cancer	0.000421	0.000511	CcSEcCtD
Budesonide—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.00042	0.00617	CbGpPWpGaD
Budesonide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00042	0.00051	CcSEcCtD
Budesonide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000418	0.000508	CcSEcCtD
Budesonide—Infection—Epirubicin—urinary bladder cancer	0.000417	0.000506	CcSEcCtD
Budesonide—Cough—Doxorubicin—urinary bladder cancer	0.000415	0.000504	CcSEcCtD
Budesonide—Shock—Epirubicin—urinary bladder cancer	0.000413	0.000502	CcSEcCtD
Budesonide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000412	0.0005	CcSEcCtD
Budesonide—Hypertension—Doxorubicin—urinary bladder cancer	0.000411	0.000499	CcSEcCtD
Budesonide—Tachycardia—Epirubicin—urinary bladder cancer	0.00041	0.000497	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000409	0.000496	CcSEcCtD
Budesonide—Skin disorder—Epirubicin—urinary bladder cancer	0.000408	0.000495	CcSEcCtD
Budesonide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000406	0.000493	CcSEcCtD
Budesonide—Insomnia—Methotrexate—urinary bladder cancer	0.000406	0.000493	CcSEcCtD
Budesonide—Chest pain—Doxorubicin—urinary bladder cancer	0.000405	0.000492	CcSEcCtD
Budesonide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000405	0.000492	CcSEcCtD
Budesonide—Myalgia—Doxorubicin—urinary bladder cancer	0.000405	0.000492	CcSEcCtD
Budesonide—Anxiety—Doxorubicin—urinary bladder cancer	0.000404	0.00049	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000404	0.00593	CbGpPWpGaD
Budesonide—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000403	0.00592	CbGpPWpGaD
Budesonide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000403	0.000489	CcSEcCtD
Budesonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000402	0.000489	CcSEcCtD
Budesonide—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000402	0.00591	CbGpPWpGaD
Budesonide—Discomfort—Doxorubicin—urinary bladder cancer	0.0004	0.000486	CcSEcCtD
Budesonide—Anorexia—Epirubicin—urinary bladder cancer	0.0004	0.000486	CcSEcCtD
Budesonide—Dyspnoea—Methotrexate—urinary bladder cancer	0.0004	0.000486	CcSEcCtD
Budesonide—Somnolence—Methotrexate—urinary bladder cancer	0.000399	0.000484	CcSEcCtD
Budesonide—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000397	0.00583	CbGpPWpGaD
Budesonide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000396	0.000481	CcSEcCtD
Budesonide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000395	0.000479	CcSEcCtD
Budesonide—Confusional state—Doxorubicin—urinary bladder cancer	0.000392	0.000476	CcSEcCtD
Budesonide—Decreased appetite—Methotrexate—urinary bladder cancer	0.00039	0.000473	CcSEcCtD
Budesonide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000388	0.000472	CcSEcCtD
Budesonide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000387	0.00047	CcSEcCtD
Budesonide—Fatigue—Methotrexate—urinary bladder cancer	0.000387	0.00047	CcSEcCtD
Budesonide—Infection—Doxorubicin—urinary bladder cancer	0.000386	0.000469	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000386	0.00567	CbGpPWpGaD
Budesonide—Pain—Methotrexate—urinary bladder cancer	0.000384	0.000466	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000382	0.000464	CcSEcCtD
Budesonide—Shock—Doxorubicin—urinary bladder cancer	0.000382	0.000464	CcSEcCtD
Budesonide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000381	0.000463	CcSEcCtD
Budesonide—Insomnia—Epirubicin—urinary bladder cancer	0.00038	0.000461	CcSEcCtD
Budesonide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000379	0.00046	CcSEcCtD
Budesonide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000377	0.000458	CcSEcCtD
Budesonide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000377	0.000458	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000376	0.00552	CbGpPWpGaD
Budesonide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000375	0.000456	CcSEcCtD
Budesonide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000374	0.000454	CcSEcCtD
Budesonide—Somnolence—Epirubicin—urinary bladder cancer	0.000373	0.000453	CcSEcCtD
Budesonide—Anorexia—Doxorubicin—urinary bladder cancer	0.00037	0.00045	CcSEcCtD
Budesonide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00037	0.000449	CcSEcCtD
Budesonide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000369	0.000449	CcSEcCtD
Budesonide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000367	0.000445	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.000365	0.00536	CbGpPWpGaD
Budesonide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000365	0.000443	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000363	0.00533	CbGpPWpGaD
Budesonide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000362	0.00044	CcSEcCtD
Budesonide—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000362	0.00532	CbGpPWpGaD
Budesonide—Fatigue—Epirubicin—urinary bladder cancer	0.000362	0.000439	CcSEcCtD
Budesonide—Pain—Epirubicin—urinary bladder cancer	0.000359	0.000436	CcSEcCtD
Budesonide—Constipation—Epirubicin—urinary bladder cancer	0.000359	0.000436	CcSEcCtD
Budesonide—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000357	0.00525	CbGpPWpGaD
Budesonide—Urticaria—Methotrexate—urinary bladder cancer	0.000356	0.000433	CcSEcCtD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.000356	0.00522	CbGpPWpGaD
Budesonide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000355	0.000431	CcSEcCtD
Budesonide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000355	0.000431	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000354	0.00043	CcSEcCtD
Budesonide—Insomnia—Doxorubicin—urinary bladder cancer	0.000351	0.000427	CcSEcCtD
Budesonide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000349	0.000424	CcSEcCtD
Budesonide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000346	0.00042	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.000346	0.00508	CbGpPWpGaD
Budesonide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000346	0.00042	CcSEcCtD
Budesonide—Somnolence—Doxorubicin—urinary bladder cancer	0.000345	0.000419	CcSEcCtD
Budesonide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000343	0.000417	CcSEcCtD
Budesonide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000342	0.000415	CcSEcCtD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.00034	0.00499	CbGpPWpGaD
Budesonide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000338	0.00041	CcSEcCtD
Budesonide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000335	0.000407	CcSEcCtD
Budesonide—Fatigue—Doxorubicin—urinary bladder cancer	0.000335	0.000407	CcSEcCtD
Budesonide—Urticaria—Epirubicin—urinary bladder cancer	0.000333	0.000405	CcSEcCtD
Budesonide—Pain—Doxorubicin—urinary bladder cancer	0.000332	0.000403	CcSEcCtD
Budesonide—Constipation—Doxorubicin—urinary bladder cancer	0.000332	0.000403	CcSEcCtD
Budesonide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000332	0.000403	CcSEcCtD
Budesonide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000332	0.000403	CcSEcCtD
Budesonide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00033	0.000401	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000324	0.00475	CbGpPWpGaD
Budesonide—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.000322	0.00474	CbGpPWpGaD
Budesonide—Asthenia—Methotrexate—urinary bladder cancer	0.000322	0.000391	CcSEcCtD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.000321	0.00471	CbGpPWpGaD
Budesonide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00032	0.000389	CcSEcCtD
Budesonide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000318	0.000386	CcSEcCtD
Budesonide—Pruritus—Methotrexate—urinary bladder cancer	0.000317	0.000385	CcSEcCtD
Budesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000312	0.00458	CbGpPWpGaD
Budesonide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000309	0.000376	CcSEcCtD
Budesonide—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.000309	0.00453	CbGpPWpGaD
Budesonide—Urticaria—Doxorubicin—urinary bladder cancer	0.000309	0.000375	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000308	0.00452	CbGpPWpGaD
Budesonide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000307	0.000373	CcSEcCtD
Budesonide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000307	0.000373	CcSEcCtD
Budesonide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000307	0.000373	CcSEcCtD
Budesonide—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.000306	0.00449	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.000305	0.00448	CbGpPWpGaD
Budesonide—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000302	0.00443	CbGpPWpGaD
Budesonide—Asthenia—Epirubicin—urinary bladder cancer	0.000301	0.000366	CcSEcCtD
Budesonide—Pruritus—Epirubicin—urinary bladder cancer	0.000297	0.000361	CcSEcCtD
Budesonide—Dizziness—Methotrexate—urinary bladder cancer	0.000297	0.00036	CcSEcCtD
Budesonide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000287	0.000349	CcSEcCtD
Budesonide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000286	0.000347	CcSEcCtD
Budesonide—Vomiting—Methotrexate—urinary bladder cancer	0.000285	0.000346	CcSEcCtD
Budesonide—Rash—Methotrexate—urinary bladder cancer	0.000283	0.000343	CcSEcCtD
Budesonide—Dermatitis—Methotrexate—urinary bladder cancer	0.000283	0.000343	CcSEcCtD
Budesonide—Headache—Methotrexate—urinary bladder cancer	0.000281	0.000341	CcSEcCtD
Budesonide—Asthenia—Doxorubicin—urinary bladder cancer	0.000279	0.000338	CcSEcCtD
Budesonide—Dizziness—Epirubicin—urinary bladder cancer	0.000278	0.000337	CcSEcCtD
Budesonide—Pruritus—Doxorubicin—urinary bladder cancer	0.000275	0.000334	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000268	0.00394	CbGpPWpGaD
Budesonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000268	0.00393	CbGpPWpGaD
Budesonide—Vomiting—Epirubicin—urinary bladder cancer	0.000267	0.000324	CcSEcCtD
Budesonide—Nausea—Methotrexate—urinary bladder cancer	0.000266	0.000324	CcSEcCtD
Budesonide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000266	0.000323	CcSEcCtD
Budesonide—Rash—Epirubicin—urinary bladder cancer	0.000265	0.000321	CcSEcCtD
Budesonide—Dermatitis—Epirubicin—urinary bladder cancer	0.000264	0.000321	CcSEcCtD
Budesonide—Headache—Epirubicin—urinary bladder cancer	0.000263	0.000319	CcSEcCtD
Budesonide—Dizziness—Doxorubicin—urinary bladder cancer	0.000257	0.000312	CcSEcCtD
Budesonide—Nausea—Epirubicin—urinary bladder cancer	0.000249	0.000303	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000248	0.00364	CbGpPWpGaD
Budesonide—Vomiting—Doxorubicin—urinary bladder cancer	0.000247	0.0003	CcSEcCtD
Budesonide—Rash—Doxorubicin—urinary bladder cancer	0.000245	0.000297	CcSEcCtD
Budesonide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000245	0.000297	CcSEcCtD
Budesonide—Headache—Doxorubicin—urinary bladder cancer	0.000243	0.000295	CcSEcCtD
Budesonide—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000241	0.00354	CbGpPWpGaD
Budesonide—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000238	0.00349	CbGpPWpGaD
Budesonide—Nausea—Doxorubicin—urinary bladder cancer	0.000231	0.00028	CcSEcCtD
Budesonide—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	0.000222	0.00326	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	0.000218	0.00321	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000213	0.00312	CbGpPWpGaD
Budesonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000213	0.00312	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000193	0.00283	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000187	0.00274	CbGpPWpGaD
Budesonide—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000182	0.00268	CbGpPWpGaD
Budesonide—NR3C1—Adipogenesis—TNF—urinary bladder cancer	0.000171	0.00251	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000164	0.00241	CbGpPWpGaD
Budesonide—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000148	0.00217	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.00013	0.0019	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000129	0.0019	CbGpPWpGaD
Budesonide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000128	0.00188	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000119	0.00175	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000118	0.00173	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	0.000118	0.00173	CbGpPWpGaD
Budesonide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000117	0.00172	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000113	0.00166	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—ESR2—urinary bladder cancer	0.000102	0.0015	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.94e-05	0.00117	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	7.91e-05	0.00116	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.52e-05	0.0011	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.52e-05	0.0011	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	7.44e-05	0.00109	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.88e-05	0.00101	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	6.71e-05	0.000986	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—ESR1—urinary bladder cancer	6.21e-05	0.000912	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.2e-05	0.00091	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.85e-05	0.000859	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.7e-05	0.000837	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—PPARG—urinary bladder cancer	5.67e-05	0.000832	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	5.45e-05	0.0008	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.56e-05	0.000669	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.12e-05	0.000605	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.56e-05	0.000523	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.3e-05	0.000484	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.3e-05	0.000484	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—MYC—urinary bladder cancer	3.23e-05	0.000475	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.2e-05	0.000469	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.66e-05	0.00039	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.22e-05	0.000325	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.06e-05	0.000302	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.04e-05	0.000299	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.04e-05	0.000299	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.95e-05	0.000286	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.91e-05	0.000281	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.8e-05	0.000264	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.46e-05	0.000214	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.4e-05	0.000206	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.15e-05	0.000169	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1e-05	0.000147	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.55e-06	0.00014	CbGpPWpGaD
